MY164577A - Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan - Google Patents

Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan

Info

Publication number
MY164577A
MY164577A MYPI2011002367A MYPI2011002367A MY164577A MY 164577 A MY164577 A MY 164577A MY PI2011002367 A MYPI2011002367 A MY PI2011002367A MY PI2011002367 A MYPI2011002367 A MY PI2011002367A MY 164577 A MY164577 A MY 164577A
Authority
MY
Malaysia
Prior art keywords
melphalan
containing antibodies
antibodies recognizing
combinations containing
recognizing specifically
Prior art date
Application number
MYPI2011002367A
Other languages
English (en)
Inventor
Pascale Lejeune
Patricia Vrignaud
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40578382&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY164577(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MY164577A publication Critical patent/MY164577A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI2011002367A 2008-11-28 2009-11-27 Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan MY164577A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08291116A EP2191840A1 (en) 2008-11-28 2008-11-28 Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan

Publications (1)

Publication Number Publication Date
MY164577A true MY164577A (en) 2018-01-15

Family

ID=40578382

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2011002367A MY164577A (en) 2008-11-28 2009-11-27 Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan

Country Status (32)

Country Link
US (1) US9259406B2 (cg-RX-API-DMAC7.html)
EP (2) EP2191840A1 (cg-RX-API-DMAC7.html)
JP (3) JP2012510461A (cg-RX-API-DMAC7.html)
KR (1) KR101733252B1 (cg-RX-API-DMAC7.html)
CN (1) CN102264385B (cg-RX-API-DMAC7.html)
AR (1) AR074219A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009321249B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0921864B1 (cg-RX-API-DMAC7.html)
CA (1) CA2744990C (cg-RX-API-DMAC7.html)
CL (1) CL2011001254A1 (cg-RX-API-DMAC7.html)
CO (1) CO6440557A2 (cg-RX-API-DMAC7.html)
CR (1) CR20110280A (cg-RX-API-DMAC7.html)
EA (1) EA026867B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP11011062A (cg-RX-API-DMAC7.html)
HN (1) HN2011001417A (cg-RX-API-DMAC7.html)
IL (1) IL213116B (cg-RX-API-DMAC7.html)
MA (1) MA32896B1 (cg-RX-API-DMAC7.html)
ME (1) ME01136B (cg-RX-API-DMAC7.html)
MX (1) MX342625B (cg-RX-API-DMAC7.html)
MY (1) MY164577A (cg-RX-API-DMAC7.html)
NI (1) NI201100105A (cg-RX-API-DMAC7.html)
NZ (1) NZ593027A (cg-RX-API-DMAC7.html)
PA (1) PA8850101A1 (cg-RX-API-DMAC7.html)
PE (1) PE20120340A1 (cg-RX-API-DMAC7.html)
SG (1) SG171820A1 (cg-RX-API-DMAC7.html)
SV (1) SV2011003924A (cg-RX-API-DMAC7.html)
TN (1) TN2011000232A1 (cg-RX-API-DMAC7.html)
TW (1) TWI454260B (cg-RX-API-DMAC7.html)
UA (1) UA107069C2 (cg-RX-API-DMAC7.html)
UY (1) UY32263A (cg-RX-API-DMAC7.html)
WO (1) WO2010061357A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201103925B (cg-RX-API-DMAC7.html)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0816777B2 (ja) 1988-10-13 1996-02-21 富士写真フイルム株式会社 画像形成方法
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP3072961A1 (en) * 2010-04-16 2016-09-28 Children's Medical Center Corporation Sustained polypeptide expression from synthetic, modified rnas and uses thereof
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
MX350540B (es) 2010-09-27 2017-09-08 Morphosys Ag Anticuerpo anti-cd38 y lenalidomida o bortezomib para el tratamiento del mieloma múltiple y nhl.
MX2013003681A (es) 2010-10-01 2013-11-20 Moderna Therapeutics Inc Ácidos nucleicos manipulados y métodos de uso de los mismos.
UA112170C2 (uk) * 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
SMT202200355T1 (it) 2011-12-16 2022-11-18 Modernatx Inc Composizioni di mrna modificato
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP2834260A4 (en) 2012-04-02 2016-08-10 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF MEMBRANE PROTEINS
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9579378B2 (en) 2012-09-25 2017-02-28 Morphosys Ag Combinations and uses thereof
EP2922554B1 (en) 2012-11-26 2022-02-23 ModernaTX, Inc. Terminally modified rna
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
UA118255C2 (uk) * 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
MX373301B (es) * 2013-10-31 2020-04-24 Sanofi Sa Anticuerpos anti-cd38 específicos para usarse para tratar cánceres humanos.
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US10617757B2 (en) 2014-08-08 2020-04-14 The Regents Of The University Of California Methods for treating multiple myeloma
SG11201701867SA (en) 2014-09-09 2017-04-27 Janssen Biotech Inc Combination therapies with anti-cd38 antibodies
PE20171094A1 (es) 2014-12-04 2017-08-07 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
BR112017024877A2 (pt) 2015-05-20 2019-09-17 Janssen Biotech, Inc. anticorpo anti-cd38 e seu uso no tratamento de amiloidose de cadeia leve e outras malignidades hematológicas positivas para cd38
CN107708734B (zh) 2015-06-22 2022-01-11 詹森生物科技公司 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
ES2912729T3 (es) 2015-11-03 2022-05-27 Janssen Biotech Inc Formulaciones subcutáneas de anticuerpos anti-CD38 y sus usos
JP7316930B2 (ja) 2016-07-15 2023-07-28 武田薬品工業株式会社 形質芽細胞及び形質細胞枯渇療法に対する応答を評価するための方法及び材料
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
CN111565751A (zh) 2017-10-31 2020-08-21 詹森生物科技公司 治疗高危多发性骨髓瘤的方法
US20210145778A1 (en) * 2018-01-01 2021-05-20 Orbicular Pharmaceutical Technologies Pvt. Ltd. Stable Liquid Compositions of Melphalan
EP3737702A1 (en) 2018-01-12 2020-11-18 Takeda Pharmaceutical Company Limited Subcutaneous dosing of anti-cd38 antibodies
WO2020069373A1 (en) 2018-09-28 2020-04-02 President And Fellows Of Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
US12274733B2 (en) 2018-09-28 2025-04-15 President And Fellows Of Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
US20220144965A1 (en) 2019-03-15 2022-05-12 Morphosys Ag Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
EP4069743A1 (en) 2019-12-05 2022-10-12 Sanofi-Aventis U.S. LLC Formulations of anti-cd38 antibodies for subcutaneous administration
WO2022152823A1 (en) 2021-01-14 2022-07-21 Morphosys Ag Anti-cd38 antibodies and their uses
TW202302642A (zh) 2021-03-01 2023-01-16 德商莫菲西斯公司 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
TW202321303A (zh) 2021-07-19 2023-06-01 德商莫菲西斯公司 抗pla2r自體抗體媒介膜性腎病變之治療
US12252518B2 (en) 2023-01-06 2025-03-18 Life Biosciences, Inc. Methods of treating non-arteritic anterior ischemic optic neuropathy

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB750155A (en) 1953-03-17 1956-06-13 Nat Res Dev Substituted alanines
US3032585A (en) 1954-12-03 1962-05-01 Nat Res Dev Process for the production of p-bis-(2-chloroethyl)-aminophenylalanine
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
AU5632296A (en) 1995-04-27 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
ATE200679T1 (de) 1997-04-14 2001-05-15 Micromet Ag Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
CA2329940A1 (en) * 1998-06-05 1999-12-09 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to cd38 to treat multiple myeloma
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
GB0221574D0 (en) 2002-09-17 2002-10-23 Isis Innovation Treatments
PL2511297T3 (pl) 2004-02-06 2015-08-31 Morphosys Ag Ludzkie przeciwciała anty-CD38 i ich zastosowania
CA2602375C (en) * 2005-03-23 2018-07-24 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
CA2664740C (en) 2006-09-26 2021-11-16 Genmab A/S Combination treatment of cd38-expressing tumors
US20080092384A1 (en) * 2006-10-16 2008-04-24 Schaake Mark D Installation of Middle Bearing for a Crankshaft
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2191843A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
EP2191841A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine

Also Published As

Publication number Publication date
AR074219A1 (es) 2010-12-29
EP2191840A1 (en) 2010-06-02
PE20120340A1 (es) 2012-04-17
AU2009321249B2 (en) 2016-06-09
JP2015205890A (ja) 2015-11-19
JP6148696B2 (ja) 2017-06-14
ME01136B (me) 2013-03-20
CN102264385A (zh) 2011-11-30
CA2744990A1 (en) 2010-06-03
BRPI0921864B1 (pt) 2022-11-16
BRPI0921864A2 (pt) 2018-10-09
ZA201103925B (en) 2012-09-26
IL213116A0 (en) 2011-07-31
TW201023855A (en) 2010-07-01
ECSP11011062A (es) 2011-07-29
AU2009321249A1 (en) 2010-06-03
CL2011001254A1 (es) 2012-01-27
MX342625B (es) 2016-10-06
TN2011000232A1 (en) 2012-12-17
IL213116B (en) 2018-11-29
SG171820A1 (en) 2011-07-28
UA107069C2 (uk) 2014-11-25
EP2370094A1 (en) 2011-10-05
SV2011003924A (es) 2011-10-07
MA32896B1 (fr) 2011-12-01
KR20110096550A (ko) 2011-08-30
CN102264385B (zh) 2015-05-20
CO6440557A2 (es) 2012-05-15
JP2017141233A (ja) 2017-08-17
US20110274686A1 (en) 2011-11-10
WO2010061357A1 (en) 2010-06-03
JP2012510461A (ja) 2012-05-10
CR20110280A (es) 2011-09-20
NZ593027A (en) 2012-12-21
NI201100105A (es) 2011-12-13
EA201100864A1 (ru) 2011-12-30
MX2011005670A (es) 2011-09-30
EA026867B1 (ru) 2017-05-31
HK1164165A1 (en) 2012-09-21
US9259406B2 (en) 2016-02-16
TWI454260B (zh) 2014-10-01
PA8850101A1 (es) 2010-07-27
CA2744990C (en) 2019-05-07
KR101733252B1 (ko) 2017-05-08
HN2011001417A (es) 2014-01-13
UY32263A (es) 2010-06-30

Similar Documents

Publication Publication Date Title
MY164577A (en) Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan
TN2011000242A1 (en) Antitumor combinations containing antibodies recognizing specifically cd38 and cytarabine
MY166530A (en) Antitumor combinations containing antibodies recognizing specifically cd38 and cyclophosphamide
TN2011000163A1 (en) Antitumor combinations containing antibodies recognizing specifically cd38 and vincristine
TN2013000245A1 (en) Antitumor combinations containing antibodies recognizing specifically cd38 and bortezomib
TN2011000153A1 (en) Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide